AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$SIBN

PISETSKY MICHAEL A. sold $57K of SIBN

PISETSKY MICHAEL A. (SVP, Ops & Adm/Chief Legal Ofr) sold 3,133 shares of SI-BONE, Inc. (SIBN) at an average of $18.17 ($18.14–$18.20) across 3 trades on 2026-10-02.

Original reporting
SEC EDGAR · PISETSKY MICHAEL A.
Published Oct 6, 2026, 11:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 11:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SIBN
Bearish
medium confidence
Mentioned
$SIBN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNBearishLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

02

Market read

Minor insider transaction with limited market impact.

03

What to watch

Insider holds 270,517 shares after the sale, indicating continued confidence.

Relevance 3/10Novelty 3/10Timing: post-filing today

Background

SEC Form 4 filing reporting an insider's open-market sale of SIBN shares.

Company-level read

Ticker impact

$SIBNBearishMedium confidence
Context

Form 4 disclosed insider Michael Pisesky sold ~57K of SIBN shares at $18.14 each.

Expected impact

likely modest pressure as the market prices the insider sell.

Evidence & confidence

The sale is small relative to float and typical for diversification; impact is limited.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

The sale could be routine and not indicative of future performance.

Key entities

  • Officer
    Michael A. Pisesky

    SVP, Ops & Adm/Chief Legal Officer at SI-BONE, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SIBN insider trading history →

Related articles

$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

rttnews.com
$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

finance.yahoo.com
$SIBNMed

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.

finance.yahoo.com